Skip to main content
PMGC Holdings Inc. logo

PMGC Holdings Inc. — Investor Relations & Filings

Ticker · ELAB ISIN · US73017P3001 US Financial and insurance activities
Open in API
Filings indexed 243 across all filing types
Latest filing 2024-10-31 Regulatory Filings
Country US United States of America
Listing US ELAB

About PMGC Holdings Inc.

https://pmgcholdings.com/

PMGC Holdings Inc. is a diversified holding company that acquires and manages cash-flowing businesses, with a primary focus on the manufacturing sector. The company operates under a long-term 'permanent capital' philosophy, aiming to preserve and grow the legacy of its acquired companies. Its strategy involves collaborating with existing founders and management teams, providing financial resources and a supportive platform to foster sustained value creation while maintaining operational continuity. PMGC Holdings actively seeks acquisitions to expand its portfolio, which includes companies in packaging and precision engineering.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 25, 2024, which is a current report pursuant to the Securities Exchange Act of 1934. The content details entry into material definitive agreements, specifically amended and restated consulting agreements for key executives (Non-Employee CEO and Non-Executive Chairman). There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is a regulatory filing reporting significant corporate events and agreements. Therefore, it fits the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), indicating it is not a mere announcement but a full filing. Hence, the classification is RNS with high confidence.
2024-10-31 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement (a Master Services Agreement and Work Order) related to clinical and regulatory services. The document includes details about the agreement, its terms, and exhibits but does not contain financial statements or quarterly/yearly financial results. It is not an earnings release, annual report, or interim report. It is a regulatory announcement of a material contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (8179 characters) and content confirm it is a full filing, not just a brief announcement or certification.
2024-10-25 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or other significant information that shareholders should know about between periodic reports. The content describes the release of preclinical data from a 2022 study related to a drug candidate, including a press release and study results as exhibits. There are no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing an event and providing related exhibits, consistent with the nature of an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7053 characters) and content confirm it is not merely a report publication announcement but a substantive regulatory filing. Confidence is high due to clear identification as a Form 8-K and the nature of the content.
2024-10-24 English
Regulatory Filings 2024
Regulatory Filings
2024-10-10 English
INFORMATION STATEMENT
Regulatory Filings Classification · 95% confidence The document is titled 'Information Statement' and is filed as a DEF 14C form with the SEC, which is used for shareholder information statements pursuant to Section 14(c) of the Securities Exchange Act of 1934. It explicitly states it is not a proxy statement and no shareholder meeting will be held. The content details shareholder actions taken by written consent, including approval of stock issuance and warrant adjustments, without a meeting or vote. The document serves to inform shareholders of these actions rather than soliciting votes or presenting financial results. It is not an annual report, earnings release, or management discussion. It is not a proxy solicitation or voting results announcement. The document is a formal regulatory filing informing shareholders of corporate actions taken by written consent, fitting the category of Regulatory Filings (RNS). The document length is substantial and contains detailed information, but it is not a financial report or presentation. Therefore, the correct classification is Regulatory Filings (RNS) with high confidence.
2024-10-10 English
SC TO-I Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to an issuer tender offer by Elevai Labs Inc. to exchange common stock for Series B Preferred Stock. The document includes references to the Offer to Exchange and related offer materials, and it explicitly states it is a Schedule TO filing. This type of filing is specifically related to tender offers and takeover bids, which falls under the M&A Activity category. The document length is 3827 characters, which is consistent with a detailed regulatory filing rather than a brief announcement. Therefore, the correct classification is M&A Activity (TAR).
2024-10-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.